Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced that it will release its second quarter 2024 financial results and corporate update on September 5, 2024. The company will host a conference call at 8:30 a.m. EDT / 14:30 CET on the same day. Investors and interested parties can access the live audio webcast of the call through the 'Webcasts' section on Affimed's website. For those who prefer to join by phone, a registration link is provided to obtain dial-in details and a pin number. To ensure a timely start, participants are encouraged to dial in 15 minutes before the scheduled time. A replay of the webcast will be available for 30 days following the call.
Affimed N.V. (Nasdaq: AFMD), un'azienda clinica nel settore dell'immuno-oncologia, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 e un aggiornamento aziendale il 5 settembre 2024. L'azienda ospiterà una conferenza telefonica il 5 settembre 2024 alle 8:30 EDT / 14:30 CET. Gli investitori e le parti interessate possono accedere alla trasmissione audio in diretta della chiamata attraverso la sezione 'Webcasts' sul sito web di Affimed. Per coloro che preferiscono partecipare telefonicamente, è fornito un link di registrazione per ottenere i dettagli di accesso e un numero PIN. Per garantire un inizio puntuale, si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario programmato. Una registrazione della trasmissione sarà disponibile per 30 giorni dopo la chiamata.
Affimed N.V. (Nasdaq: AFMD), una empresa de inmuno-oncología en etapa clínica, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y una actualización corporativa el 5 de septiembre de 2024. La empresa llevará a cabo una conferencia telefónica el 5 de septiembre de 2024 a las 8:30 a.m. EDT / 14:30 CET. Los inversionistas y partes interesadas pueden acceder a la transmisión de audio en vivo de la llamada a través de la sección 'Webcasts' en el sitio web de Affimed. Para aquellos que prefieren unirse por teléfono, se proporciona un enlace de registro para obtener los detalles de acceso y un número PIN. Para asegurar un inicio puntual, se alienta a los participantes a marcar 15 minutos antes de la hora programada. Una grabación de la transmisión estará disponible durante 30 días después de la llamada.
Affimed N.V. (Nasdaq: AFMD)는 임상 단계의 면역 종양학 회사로, 2024년 2분기 재무 결과 및 기업 업데이트를 2024년 9월 5일에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 EDT / 오후 2시 30분 CET에 전화 회의를 개최합니다. 투자자 및 관계자는 Affimed 웹사이트의 'Webcasts' 섹션을 통해 전화 회의의 라이브 오디오 웹캐스트에 접속할 수 있습니다. 전화를 통해 참여하고자 하는 분들을 위해 등록 링크가 제공되어 접속 정보와 PIN 번호를 얻을 수 있습니다. 정시에 시작할 수 있도록 참가자들은 예정된 시간 15분 전에 전화 접속할 것을 권장합니다. 회의 후 30일 동안 웹캐스트 재녹음이 제공될 것입니다.
Affimed N.V. (Nasdaq: AFMD), une entreprise d'immuno-oncologie en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et une mise à jour de l'entreprise le 5 septembre 2024. L'entreprise tiendra une conférence téléphonique le 5 septembre 2024 à 8h30 EDT / 14h30 CET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion audio en direct de l'appel via la section 'Webcasts' sur le site web d'Affimed. Pour ceux qui préfèrent rejoindre par téléphone, un lien d'inscription est fourni pour obtenir les détails de connexion et un numéro PIN. Afin de garantir un début à l'heure, les participants sont invités à se connecter 15 minutes avant l'heure prévue. Un enregistrement de la diffusion sera disponible pendant 30 jours suivant l'appel.
Affimed N.V. (Nasdaq: AFMD), ein Unternehmen der klinischen Immunonkologie, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 und ein Unternehmensupdate am 5. September 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr EDT / 14:30 Uhr CET eine Telefonkonferenz abhalten. Investoren und Interessierte können die Live-Audio-Übertragung der Konferenz im Bereich 'Webcasts' auf der Website von Affimed verfolgen. Für diejenigen, die lieber telefonisch teilnehmen möchten, wird ein Registrierungslink bereitgestellt, um die Einwahldaten und eine PIN zu erhalten. Um einen pünktlichen Beginn zu gewährleisten, werden die Teilnehmer ermutigt, 15 Minuten vor der geplanten Zeit einzuwählen. Eine Aufnahme der Übertragung wird 30 Tage nach der Konferenz verfügbar sein.
- None.
- None.
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2024 results and corporate update on Thursday, September 5, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.
The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link
https://register.vevent.com/register/BI53034c7725d043b0854377307e1cd8a3, and you will be provided with dial-in details and a pin number.
Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
FAQ
When will Affimed (AFMD) report its Q2 2024 financial results?
What time is Affimed's (AFMD) Q2 2024 earnings call scheduled for?
How can investors access Affimed's (AFMD) Q2 2024 earnings call?
Will there be a replay available for Affimed's (AFMD) Q2 2024 earnings call?
